{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '111', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '9.5', 'Analysis Populations', '9.5.1', 'Efficacy Analysis Populations', 'The analyses of the primary efficacy endpoints are based on the ITT population. All', 'randomized participants will be included in this population. Participants will be analyzed in', 'the treatment group to which they are randomized. Details on the approach to handling', 'missing data are provided in Section 9.6.', 'Extension Study in China', 'NOTE: As of Amendment 007-06, enrollment in the Extension Study in China has been', 'stopped. This section has been updated accordingly.', 'The participants in China who were randomized in the extension study will not be included', 'in the above global study primary efficacy analysis population. The ITT participants in China,', 'including all participants in China randomized in the global study and the extension study,', 'will be analyzed.', '9.5.2 Safety Analysis Populations', 'Safety analyses will be conducted in the APaT population, which consists of all randomized', 'participants who received at least 1 dose of study intervention. Participants will be included', 'in the treatment group corresponding to the study intervention they actually received for the', 'analysis of safety data using the APaT population. This will be the treatment group to which', 'they were randomized, except for participants who take incorrect study intervention for the', 'entire treatment period; such participants will be included in the treatment group', 'corresponding to the study intervention actually received. Any participant who receives the', 'incorrect study intervention for 1 cycle, but receives the randomized treatment for all other', 'cycles, will be analyzed according to the randomized treatment group, and a narrative will be', 'provided for any events that occur during the cycle for which the participant is incorrectly', 'dosed.', 'At least 1 laboratory, vital sign, or ECG measurement obtained after at least 1 dose of study', 'intervention is required for inclusion in the analysis of the respective safety parameter. To', 'assess change from baseline, a baseline measurement is also required.', 'Extension Study in China', 'The participants in China who were randomized and treated in the extension study will not be', 'included in the above global study primary safety analysis population. The APaT participants', 'in China, including all randomized participants in China (in the global study and extension', 'study) who received at least 1 dose of study treatment, will be analyzed.', '9.5.3 Patient-reported Outcome Analysis Population', 'The analyses of PRO endpoints will be based on the PRO full analysis set (FAS) population', 'following the ITT principle and ICH E9 guidelines. The PRO FAS population consists of all', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '112', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'randomized participants who have received at least 1 dose of study intervention and have', 'completed at least 1 PRO assessment.', '9.5.4 Pharmacokinetic Analysis Population', 'The population of PK analysis set includes all the participants who have received at least', '1 dose of study intervention with documented dosing history in the lenvatinib +', 'pembrolizumab arm and have measurable plasma levels of lenvatinib or serum levels of', 'pembrolizumab.', '9.6', 'Statistical Methods', 'NOTE: As of Amendment 007-06, the prespecified interim and final analyses of the', 'study will not be performed. Selected analyses of safety and ePRO endpoints will be', 'performed at end of study; there will be no further analyses of efficacy endpoints. The', 'subsections below are retained for reference.', '9.6.1', 'Statistical Methods for Efficacy Analyses', 'This section describes the statistical methods that address the primary and secondary efficacy', 'objectives. Methods related to exploratory objectives will be described in the sSAP. Efficacy', 'results that will be deemed to be statistically significant after consideration of the Type I', 'error control strategy are described in Section 9.8. Nominal p values will be computed for', 'other efficacy analyses, but should be interpreted with caution because of potential issues of', 'multiplicity.', 'The stratification factors used for randomization (see Section 6.3.2) will be applied to all', 'stratified analyses, in particular, the stratified log-rank test, stratified Cox model, and', 'stratified Miettinen and Nurminen method [Miettinen, O. 1985]. If there are small strata, for', 'the purpose of analysis, strata will be combined to ensure sufficient number of participants,', 'responses and events in each stratum. Details regarding the pooling strategy will be', 'prespecified in the sSAP prior to the database lock for the first analysis when each applicable', 'endpoint will be analyzed, and decisions regarding the pooling will be based on a blinded', 'review of response and event counts by stratum.', 'The efficacy analyses for OR, DOR and PFS will include responses and documented', 'progression events that occur prior to Second-course treatment.', 'A summary of the primary analysis strategy for the key efficacy endpoints is provided in', 'Table 7.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}